Does it really matter if you win or lose the genetic lottery?
By Joseph L Graves Jr,
The Lancet
| 01. 01. 2022
Kathryn Paige Harden, Professor of Psychology who leads the Developmental Behavior Genetics lab at the University of Texas at Austin, USA, is considered by many in her field as an up and coming superstar. Her book, The Genetic Lottery: Why DNA Matters for Social Equality, proposes that an individual's genetic composition, specifically related to their capacity to succeed at education, has an important role in determining their social outcomes. Harden examines the role that an individual's genetic predisposition may have in contributing to their position in society.
To make her case, Harden relies on, for example, results of studies that have associated polygenic scores (PGS) with educational attainment. PGS are derived from genome-wide association studies and identify variants that are statistically associated with a given phenotype. Harden summarises results from a series of PGS studies that indicate that they predict educational attainment, and that educational attainment is associated with a number of social outcomes including greater wealth. None of this is particularly controversial to people who know genetics. The traits of all organisms, behavioural and otherwise, result from the complex... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...